Dottikon ES Holding AG
269.08
CHF
+10.77
(+4.17%)
ISIN
CH0582581713
Return %
Stock
S&P 500
1Y
-13.14
14.20
3Y
25.29
81.12
5Y
- -
68.34
Capital Structure
CHF
•
in mil. unless spec.Working Capital
CHF
•
in mil. unless spec.Growth Rates
CHF
•
in mil. unless spec.Semi-annual Revenue
CHF
•
in mil. unless spec.Semi-annual Earnings Per Share
CHF
•
in mil. unless spec.Semi-annual Dividends Per Share
CHF
•
in mil. unless spec.Company Description
- CEO
- Markus Blocher
- Full Time Employees
- 900
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- Hembrunnstrasse 17 Dottikon AG Switzerland 5605
- IPO Date
- Mar 22, 2005
- Website
- dottikon.com
- Similar Companies
- Business
- Dottikon ES Holding AG specializes in the development and manufacture of fine chemicals, with a primary focus on active pharmaceutical ingredients (APIs), pharmaceutical intermediates, performance chemicals, and hazardous chemistry products. The company offers exclusive synthesis services, custom chemical manufacturing from grams to multi-tons, process development, routefinding, project management, and quality management compliant with cGMP and ICH guidelines. Its product portfolio includes APIs used in medications targeting heart disease, asthma, high blood pressure, and ulcers, alongside performance chemicals such as aromatic and alicyclic diamines, bio-based organosilanes, and phlegmatized azides for high-performance polymers, adhesives, composites, and crosslinking agents. Additionally, it provides industrial chemicals for food additives, cosmetics, electro-chemicals, photo-chemicals, and agricultural chemicals, as well as equipment for solvent recycling and hazardous waste treatment. Dottikon ES Holding operates primarily from its headquarters and manufacturing site in Dottikon, Switzerland, serving global pharmaceutical and chemical industry clients. Founded in 1913, the company has a long history and holds two wholly owned subsidiaries: Dottikon Exclusive Synthesis AG and Dottikon ES Management AG. Major shareholders include EVOLMA Holding AG, which controls 57% of shares, and CEO Markus Blocher, a significant individual shareholder. In the latest business developments for 2025/26, Dottikon ES Holding reports substantial growth in net sales, earnings, and cash flow, driven by broad-based product and customer expansion. The company is actively investing in expanding its chemical small-scale manufacturing plant and pilot plant for APIs, nearly doubling high-quality manufacturing capacities to capture increasing market demand for innovative, patent-protected small-molecule APIs outsourced from biopharma companies. These expansions reinforce its one-site strategy as a specialist partner for hazardous chemical reactions. The company reaffirms its focus on process development and manufacturing of APIs and pursues opportunities in the industrial chemicals market. Recent half-year results indicated a 24.9% rise in net sales to CHF 196.1 million and an EBIT increase of 50% to CHF 56.0 million, with further investments planned to support growth and capacity enhancements. Dottikon ES Holding maintains compliance with relevant pharmaceutical and chemical quality standards and continues to launch several API productions annually while supporting regulatory filings and stability testing. Its strategic focus includes growth in innovative pharmaceutical ingredient outsourcing and expanding its performance chemicals business segment internationally. This comprehensive specialization and ongoing strategic investments position Dottikon ES Holding AG as a leading chemical manufacturer in the pharmaceutical and specialized industrial chemical sectors headquartered in Switzerland.